Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Myelofibrosis as a model to study the early evolution of stem cells that drive acute myeloid leukemia development.
EF 2019-20
Résumé
Acute myeloid leukemia (AML) is a dismal disease that results from the accumulation of genetic mutations in stem cells that normally work to maintain the blood system over an individual's lifespan. Although AML occurs with little clinical warning prior to diagnosis, recent advancements have clearly shown the presence of a pre-leukemic phase. While leukemic mutations are found in the blood of normal individuals, the high incidence of these mutations but low incidence of AML, argues that the vast majority people carrying "leukemic mutations" will never develop disease. Thus, the true preleukemic phase and the stem cells that drive its progression towards disease have been virtually inaccessible for study and early leukemia development remains a black box.
While most AML cases are diagnosed de novo, some progress from a preceding blood disease, such as myelofibrosis (MF). MF is a high-risk malignancy, owing to its high transformation rate to AML, which is invariably fatal. Importantly, while AML onset is sudden and rapid, MF is a chronic disease. Thus, serial sampling over the entire course of MF pathogenesis represents a unique opportunity for unparalleled access to the preleukemic phase and the stem cells that drive it.
I aim to study the entire arc of disease progression from the cell of origin to MF to AML. I will precisely study the stem cell populations that our group have previously found to be responsible for MPN initiation and leukemic progression. Using patient samples from biobanks and novel single cell approaches, I will track and characterize these stem cells at timepoints before diagnosis, during MF and at the time of progression to AML. A battery of computational approaches will be used to elucidate the key stem cell features responsible for disease initiation and progression. This approach will provide insights that facilitate early detection and intervention strategies that target pre-leukemic stem cells prior to their development of frank leukemia.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
417309
Name
Medeiros Jessie J
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Myelofibrosis as a model to study the early evolution of stem cells that drive acute myeloid leukemia development.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Ageing; Bioinformatics; Cellular Evolution; Genetics; Myelofibrosis; Stem Cells
Abstract
Acute myeloid leukemia (AML) is a dismal disease that results from the accumulation of genetic mutations in stem cells that normally work to maintain the blood system over an individual's lifespan. Although AML occurs with little clinical warning prior to diagnosis, recent advancements have clearly shown the presence of a pre-leukemic phase. While leukemic mutations are found in the blood of normal individuals, the high incidence of these mutations but low incidence of AML, argues that the vast majority people carrying "leukemic mutations" will never develop disease. Thus, the true preleukemic phase and the stem cells that drive its progression towards disease have been virtually inaccessible for study and early leukemia development remains a black box.
While most AML cases are diagnosed de novo, some progress from a preceding blood disease, such as myelofibrosis (MF). MF is a high-risk malignancy, owing to its high transformation rate to AML, which is invariably fatal. Importantly, while AML onset is sudden and rapid, MF is a chronic disease. Thus, serial sampling over the entire course of MF pathogenesis represents a unique opportunity for unparalleled access to the preleukemic phase and the stem cells that drive it.
I aim to study the entire arc of disease progression from the cell of origin to MF to AML. I will precisely study the stem cell populations that our group have previously found to be responsible for MPN initiation and leukemic progression. Using patient samples from biobanks and novel single cell approaches, I will track and characterize these stem cells at timepoints before diagnosis, during MF and at the time of progression to AML. A battery of computational approaches will be used to elucidate the key stem cell features responsible for disease initiation and progression. This approach will provide insights that facilitate early detection and intervention strategies that target pre-leukemic stem cells prior to their development of frank leukemia.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Medeiros, Jessie J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~